Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- citrullinated fibrinogen antibody mouse plasma serum arthritis assay kit service autoimmune disease EIA enzyme immunoassay immunology inflammation ELISA anticitrullinated anti
- Product Overview:
Immunization of mice with citrullinated human fibrinogen, especially mice expressing the human HLA-DR4 transgene, induces an arthritic response driven by the production of antibodies that recognize citrullinated epitopes. The polyclonal antibody response produces antibodies reactive with both citrullinated human fibrinogen and unmodified, noncitrullinated human fibrinogen. Cayman’s Anti-Citrullinated Human Fibrinogen Assay (mouse) is an immunometric (sandwich) assay that can be used to distinguish the antibody response to citrullinated human fibrinogen from the antibody response to unmodified human fibrinogen in mouse serum or plasma. A human fibrinogen affinity sorbent is provided with the kit so that any antibodies capable of reacting with non-citrullinated (unmodified) fibrinogen can be removed prior to analysis of the remaining anti-citrullinated fibrinogen antibodies for an accurate analysis of the anti-citrulline response. This kit uses a citrullinated human fibrinogen-coated plate and a detection antibody recognizing mouse IgG. An anti-citrullinated human fibrinogen monoclonal antibody is included as a standard. The standard curve spans the range of 0.15 to 10 µg/ml, with an an LLOQ of 0.15 µg/ml.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.